Crocs, Inc.
CROX
$118.19
+0.08%
Crocs, Inc. designs, develops, markets, and distributes casual lifestyle footwear and accessories for men, women, and children, operating through two reportable segments — the core Crocs Brand and the acquired HEYDUDE Brand — within the global apparel and footwear industry. The company is best characterized as a high-margin, cash-generative niche leader whose iconic clog silhouette and molded-footwear manufacturing model give it a distinct cost and brand-identity advantage over traditional athletic and fashion footwear competitors. The current investor narrative is dominated by the turnaround of the HEYDUDE brand, which management has been repositioning after a period of severe underperformance, alongside the durability of the core Crocs franchise and the company's aggressive share-repurchase program. Recent headlines and analyst actions reflect this tension: several firms upgraded the stock in mid-2026 citing brand recovery and an attractive valuation, while others continue to flag HEYDUDE as a lingering overhang, and the market remains divided on whether the single-digit forward earnings multiple represents deep value or a value trap.…
CROX
Crocs, Inc.
$118.19
Related headlines
Investment Opinion: Should I buy CROX Today?
The synthesized recommendation for CROX is a Buy with a medium confidence level, based on the compelling valuation and strong cash flow generation. The core thesis is that the market is overly discounting the HEYDUDE overhang and underappreciating the cash-generative core Crocs brand, as evidenced by the forward P/E of 7.9x and the average analyst target of $138.25 (17% upside). While the analyst consensus recommendation is not explicitly provided, the average target and recent upgrades suggest a favorable view.
The supporting evidence is robust: (1) Valuation is deeply discounted, with a forward P/E of 7.9x and PEG of 0.52, well below typical consumer discretionary multiples. (2) Revenue growth is positive but modest at 2.6% YoY, though the core Crocs brand likely grew faster. (3) Profitability is strong, with a 59.4% gross margin and 24.2% operating margin in Q2 2026, and net income of $204.9M. (4) Free cash flow is substantial at $704.6M TTM, enabling share buybacks that reduced shares outstanding by 15.8% from Q3 2024 to Q2 2026. (5) The implied upside to the average analyst target is 17.1%, with the high target at $163 (38% upside).
The biggest risks that could invalidate this thesis are: (1) A further deterioration in HEYDUDE leading to additional impairments and cash burn. (2) A consumer spending slowdown that pressures the core brand's sales and margins. (3) High leverage (D/E 1.25) limiting financial flexibility. The rating would upgrade to a strong Buy if HEYDUDE returns to profitability or is divested at a reasonable price, and if revenue growth accelerates above 5%. It would downgrade to Hold if revenue growth turns negative or if gross margins fall below 55%. Relative to its history and peers, CROX appears undervalued on a forward earnings basis, but the market is pricing in significant uncertainty, so the stock is fairly valued to slightly undervalued with a favorable risk/reward skew.
Sign up to view all
CROX 12-Month Price Forecast
CROX presents a compelling risk/reward proposition, with the market overly focused on the HEYDUDE overhang while undervaluing the cash-generative core business. The forward P/E of 7.9x and PEG of 0.52 suggest the stock is priced for stagnation, yet the company generates substantial free cash flow and has a proven ability to buy back shares. The bull case is supported by analyst targets and recent upgrades, but the bear case cannot be dismissed given the high leverage and competitive pressures. I would upgrade to high confidence if HEYDUDE shows clear signs of stabilization or if the company announces a value-accretive divestiture. Conversely, I would downgrade to neutral if revenue growth turns negative or if gross margins fall below 55%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Crocs, Inc.'s 12-month outlook, with a consensus price target around $138.25 and implied upside of +17.0% versus the current price.
Average Target
$138.25
0 analysts
Implied Upside
+17.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$95 - $163
Analyst target range
Bulls vs Bears: CROX Investment Factors
The bull case for CROX rests on its compelling valuation (7.9x forward P/E, 0.52 PEG), robust free cash flow ($704.6M TTM), and the core Crocs brand's high margins (59.4% gross, 24.2% operating). The bear case centers on the HEYDUDE overhang, which has already caused a $759M impairment and continues to cloud earnings visibility, alongside elevated leverage (D/E 1.25) and slowing top-line growth (2.6% YoY). Currently, the bull evidence appears stronger: the stock has delivered 37% one-year returns, analyst targets imply 17% upside, and the forward multiple is deeply discounted. The single most important tension is whether HEYDUDE can be stabilized or divested without further value destruction; if it turns profitable, the stock could re-rate sharply, but if it deteriorates further, the value trap narrative could prevail.
Bullish
- Deep value on forward earnings: CROX trades at a forward P/E of just 7.9x based on estimated EPS of $14.83, a steep discount to the broader market and its own historical multiple. The PEG ratio of 0.52 further suggests the stock is priced for minimal growth despite analyst revenue estimates of $4.56B.
- Strong free cash flow generation: The company generated $704.6M in trailing twelve-month free cash flow, which represents roughly 15% of its $4.64B market cap. This cash generation supports the aggressive share buyback program, with shares outstanding declining from 59.0M in Q3 2024 to 49.7M in Q2 2026.
- Core Crocs brand remains highly profitable: Q2 2026 gross margin was 59.4% and operating margin was 24.2%, demonstrating the pricing power and cost advantage of the molded-footwear model. Net income in Q2 2026 was $204.9M, a sharp recovery from the -$492.3M loss in Q2 2025 that was driven by a $759M HEYDUDE impairment charge.
- Analyst targets imply significant upside: The average analyst price target of $138.25 represents 17.1% upside from the current price of $118.09, with the high target of $163 implying 38% upside. This comes after multiple analyst upgrades in mid-2026 citing brand recovery and attractive valuation.
Bearish
- HEYDUDE remains a major overhang: The HEYDUDE acquisition has been a persistent drag, evidenced by the $759.2M impairment charge in Q2 2025 that caused a quarterly net loss of $492.3M. Despite management's turnaround efforts, the brand's recovery timeline remains uncertain and continues to weigh on investor sentiment.
- Negative trailing earnings and ROE: The trailing P/E is -57.0x due to a trailing EPS of -$0.0175, and ROE is -6.3%, reflecting the impact of the HEYDUDE writedown. While these are backward-looking, they highlight the earnings volatility and the risk that further charges could emerge.
- Elevated debt and leverage: The debt-to-equity ratio of 1.25 is high for a consumer discretionary company, and interest expense remains significant at $60.8M in Q2 2026 alone. This leverage amplifies risk if revenue growth stalls or if refinancing conditions worsen.
- Slowing revenue growth: Q2 2026 revenue grew only 2.6% year-over-year to $1.18B, a modest pace that may not justify a premium multiple. The 3-month price change is -5.7%, underperforming the S&P 500's +3.3%, suggesting near-term momentum has faded.
CROX Technical Analysis
Beta
1.56
1.56x market volatility
Max Drawdown
-24.3%
Largest decline past year
52-Week Range
$73-$141
Price range past year
Annual Return
+39.2%
Cumulative gain past year
| Period | CROX Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | +0.6% |
| 3m | -5.1% | +3.6% |
| 6m | +21.7% | +14.6% |
| 1y | +39.2% | +15.8% |
| ytd | +35.9% | +13.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CROX Fundamental Analysis
Quarterly Revenue
$1.2B
2026-06
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
59.4%
Latest Quarter
Free Cash Flow
$704620000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CROX Overvalued?
PE
-57.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~16x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks for CROX are significant. The debt-to-equity ratio of 1.25 is elevated for a consumer discretionary firm, and interest expense of $60.8M in Q2 2026 consumes a meaningful portion of operating income ($285.7M). The current ratio of 1.27 is adequate but not robust, leaving limited buffer if cash flows decline. Additionally, the HEYDUDE segment has already required a $759.2M impairment charge in Q2 2025, and further write-downs or restructuring costs could pressure earnings and erode shareholder equity, which is already reflected in the negative ROE of -6.3%. Revenue concentration in the core Crocs brand (which accounts for the majority of sales) means any slowdown in that franchise would disproportionately impact overall results.
Market and competitive risks are amplified by CROX's high beta of 1.51, indicating it is 51% more volatile than the broader market. The stock's 3-month relative strength is -9.1 percentage points versus the S&P 500, highlighting recent underperformance and potential sector rotation risk. The footwear industry is highly competitive, with traditional athletic brands and fast-fashion players constantly vying for market share; Crocs' reliance on a single iconic silhouette (the clog) exposes it to shifting consumer preferences. Furthermore, the short ratio of 4.84 suggests that bearish sentiment remains entrenched, and any negative news could trigger a short-selling cascade. Recent analyst upgrades have been offset by continued concerns over HEYDUDE, and the market remains divided on whether the low multiple is a value opportunity or a trap.
The worst-case scenario for CROX would involve a renewed deterioration in HEYDUDE, leading to another impairment charge, combined with a slowdown in the core Crocs brand and a macro-driven consumer pullback. In such a scenario, the stock could retest its 52-week low of $73.21, representing a 38% decline from the current price of $118.09. The analyst low target of $95.00 implies a 19.6% downside, but if earnings disappoint and the forward P/E compresses to 5x on lower EPS estimates, the downside could be more severe. A realistic bear-case target of $85 would equate to a 28% loss from current levels, and if the company's leverage becomes a concern, a deeper sell-off to the $70s is possible. Investors should be prepared for drawdowns given the stock's historical max drawdown of -24.25% and its high beta.
FAQ
The key risks include: (1) HEYDUDE turnaround failure, which could lead to further impairments and cash burn, as seen with the $759M charge in Q2 2025; (2) High leverage with a debt-to-equity of 1.25 and interest expense of $60.8M per quarter, which could strain finances if earnings decline; (3) Competitive pressures in the footwear industry, where trends can shift rapidly, and CROX's reliance on a single silhouette is a vulnerability; (4) Macroeconomic sensitivity, as consumer discretionary spending may weaken in a recession, and the stock's beta of 1.51 amplifies market downturns. Additionally, a short ratio of 4.84 indicates bearish sentiment that could exacerbate volatility.
The 12-month forecast for CROX includes three scenarios: a bull case with 30% probability targeting $150-$163 if HEYDUDE stabilizes and the core brand grows; a base case with 50% probability targeting $130-$145, aligned with the analyst average of $138.25, assuming modest growth and no further impairments; and a bear case with 20% probability targeting $73-$95 if HEYDUDE deteriorates and consumer spending weakens. The base case is most likely, hinging on stable gross margins and continued share buybacks. Analyst estimates for EPS average $14.83, which supports the valuation case.
CROX appears undervalued on a forward earnings basis, trading at a forward P/E of 7.9x compared to the broader market's mid-to-high teens multiple. The PEG ratio of 0.52 suggests the stock is cheap relative to its expected growth, and the price-to-sales ratio of 1.15 is low for a company with 59% gross margins. However, the trailing P/E is negative due to the HEYDUDE impairment, and the EV/EBITDA of 25.4x is elevated because EBITDA was depressed by the charge. The market is pricing in significant uncertainty around HEYDUDE, but if the brand stabilizes, the multiple could expand toward historical levels.
CROX appears to be a good buy for value-oriented investors with a medium-term horizon, given its forward P/E of 7.9x and 17.1% upside to the average analyst target of $138.25. The company generates $704.6M in trailing free cash flow, which supports buybacks and debt reduction, and the core Crocs brand boasts a 59.4% gross margin. However, the HEYDUDE overhang and high debt-to-equity of 1.25 introduce significant risk, and the stock's beta of 1.51 means it can be volatile. It is best suited for investors who can tolerate short-term drawdowns and believe in the HEYDUDE turnaround. A diversified portfolio approach is recommended.
CROX is more suitable for a medium-to-long-term investment horizon of at least 2-3 years, given the ongoing HEYDUDE turnaround and the company's focus on debt reduction and share buybacks. The stock does not pay a dividend, so returns depend on capital appreciation, and its high beta of 1.51 makes it prone to short-term volatility, which could be exploited by traders but poses risks for short-term holders. The deep value and strong cash flow suggest that patient investors could be rewarded as the market recognizes the core brand's worth. A minimum holding period of 18-24 months is recommended to allow the HEYDUDE strategy to play out.